Plump is due to step down in June 2027. Until then, he will continue in the role of president of R&D – and remain a member of ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...

Some pharmacists in England can now prescribe medicines for acne, migraines, scabies, ear infections, and rhinitis in a major expansion of the Pharmacy First scheme first introduced in 2024. The five ...

Susan Marlin, chief executive of Clinical Trials Ontario, and Invest Ontario's life sciences lead Garrett Tone, say changes ...

The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin ...

Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell ...

Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...